Canine adenovirus type 2 vector generation via I-Sce1-mediated intracellular genome release

PLoS One. 2013 Aug 1;8(8):e71032. doi: 10.1371/journal.pone.0071032. Print 2013.

Abstract

When canine adenovirus type 2 (CAdV-2, or also commonly referred to as CAV-2) vectors are injected into the brain parenchyma they preferentially transduce neurons, are capable of efficient axonal transport to afferent regions, and allow transgene expression for at last >1 yr. Yet, translating these data into a user-friendly vector platform has been limited because CAV-2 vector generation is challenging. Generation of E1-deleted adenovirus vectors often requires transfection of linear DNA fragments of >30 kb containing the vector genome into an E1-transcomplementing cell line. In contrast to human adenovirus type 5 vector generation, CAV-2 vector generation is less efficient due, in part, to a reduced ability to initiate replication and poor transfectibility of canine cells with large, linear DNA fragments. To improve CAV-2 vector generation, we generated an E1-transcomplementing cell line expressing the estrogen receptor (ER) fused to I-SceI, a yeast meganuclease, and plasmids containing the I-SceI recognition sites flanking the CAV-2 vector genome. Using transfection of supercoiled plasmid and intracellular genome release via 4-OH-tamoxifen-induced nuclear translocation of I-SceI, we improved CAV-2 vector titers 1,000 fold, and in turn increased the efficacy of CAV-2 vector generation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenoviruses, Canine / genetics*
  • Animals
  • Cell Line
  • DNA Breaks, Double-Stranded
  • DNA, Superhelical
  • Deoxyribonucleases, Type II Site-Specific / metabolism*
  • Dogs
  • Genetic Vectors / genetics*
  • Genome / genetics*
  • Intracellular Space / genetics*
  • Plasmids / genetics
  • Receptors, Estrogen / genetics
  • Saccharomyces cerevisiae Proteins / metabolism*
  • Transfection / methods*

Substances

  • DNA, Superhelical
  • Receptors, Estrogen
  • Saccharomyces cerevisiae Proteins
  • SCEI protein, S cerevisiae
  • Deoxyribonucleases, Type II Site-Specific

Grants and funding

Funding was provided by European Commission through European Community’s 7th Framework Program (FP7/2007–2013; grant 222992, BrainCAV), the Region Languedoc Roussillon (ARPE and CTP 115277), the Fondation de France (grant number 2008005416), Vaincre les Maladies Lysosomales (VML). Motor Neurone Disease Association and Agence National de la Recherche (program Blanc, E-RARE and MNP), and the Association Francaise contre les Myopathies. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.